1. Ex-FDA Chief Gottlieb says regulator needs to up pace on COVID-19 drugs— Gilead won't be charging for use of experimental COVID drug, for now — FDA backs first emergency COVID-19 antibody test from Cellex — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Worst move I ever made coming here!!

Discussion in 'Neurocrine' started by anonymous, Aug 1, 2017 at 12:52 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    This company is filled with nothing but female posers. DP needs to be shown the door. Her decisions are bad for the company and will eventually get us in trouble, just like before.
     

  2. anonymous

    anonymous Guest

    Why are we paying DP's legal bills for crap she did at AVR? Who is running this show? We are not generating enough income to be doing this. I understand the internal investigation but this in unreal. Look at who just resigned and follow the clues to the DOJ.
     
  3. anonymous

    anonymous Guest

    It doesn't matter wey keep the BJ Giving Directors we have. Both were run out of their last companies, both filled their teams with repeated failures for the management teams, all have led to us getting our ass kicked very quickly. No coverage, changing our setup, freaking diabetes reps and managers having no clue and now on top of it al....THE DOJ
     
  4. anonymous

    anonymous Guest

    Zero cash coming in, zero. They convinced us the product would be covered and delivered, neither of the two have occurred more than 1/10 times
     
  5. anonymous

    anonymous Guest

    I am getting nothing but complaints about product accessibility. There are only so many excuses I can make up for all these hiccups.
     
  6. anonymous

    anonymous Guest

     
  7. anonymous

    anonymous Guest

    what r u all talking abt? I’m already at quota for year end, and it’s only mid October. Collected 3300k train bonus, 14k partial bonus and looks like 28K in January. Plus 123k/yr salary. Plus 500/month car allowance.
     
  8. anonymous

    anonymous Guest

    It is afflicted. You are a bunch of dumb shits. Ha
     
  9. anonymous

    anonymous Guest

    Seriously I'm so not complaining! It takes some work but they are going through and there are plenty of patients to be had.
     
  10. anonymous

    anonymous Guest

    IF YOU WANT TO SELL THIS PRODUCT GO TO NEUROLOGY. TD IS A MOVEMENT DISORDER.
     
  11. anonymous

    anonymous Guest

    Avanir's Nuedexta promotion was featured in CNN story. They have more names to name with the questionable promotion.. and the DOJ investigation is ongoing. Those names are going to make Neurocrine look bad as the Avanir cast offs are here now. Thanks for nothing DP, FM and more........
     
  12. anonymous

    anonymous Guest

    I was curious to see how things were going at NBS. I interviewed but did not get hired. I guess now I am truly glad. Truly wish good luck to you all.
     
  13. anonymous

    anonymous Guest

    I think the saying refers to being a b***h. "It takes one to know one."
     
  14. anonymous

    anonymous Guest

    How is it going there ?
    Are there really that many TD patients?
    Are psychs writing your drug ?
     
  15. anonymous

    anonymous Guest

    There is going to be a sales force expansion this fall. Anticipated launch of a Parkinson's drug.
     
  16. anonymous

    anonymous Guest

    They might file a Parkinson's drug in June and then wait a year to see if it gets approved. Best case, there'll be no Parkinson's drug to launch until mid-summer 2020.
     
  17. anonymous

    anonymous Guest

    June?! Ono filed in Feb. What's the holdup?
     
  18. anonymous

    anonymous Guest

    You can expect more if a delay since FDA is reacting to the Kung Flu